Combination therapy with ARN3261 and olaparib synergistically decreased cell viability at the doses optimized for synergy using 2 PARP inhibitor–resistant ovarian cancer cell lines (unpublished observations). This evidence concerns the gene PARP1 and ovarian cancer.